Eisai Eyes Longer-Lasting Stomach Acid Drug (Japan)
This article was originally published in PharmAsia News
Executive SummaryEisai Co. is working on a follow-up to Pariet, its drug for stomach ulcers, acid reflux, and related gastrointestinal problems. U.S. patents on Pariet, which is sold in America as Aciphex, expire in May 2013. Eisai hopes to have the new product ready by May 2013, when U.S. patents on the drug, which is marketed in the United States as Aciphex, expire. Eisai says the new drug will be longer-lasting and more effective than Pariet at blocking secretion of stomach acid at night. The third and final phase of clinical testing will begin as early as 2008 in the U.S. The company plans to apply for marketing approval in fiscal 2009. (Click here for more - May Require Paid Subscription
You may also be interested in...
A revised procedure is in place to temporarily list unlicensed products for use in public health emergencies.
Pfizer has announced that it does not plan to market its Amsparity adalimumab biosimilar in Europe despite it having been endorsed by the EMA in December and being in line for an imminent approval from the European Commission.
Developers of arthroscopy tubing should take additional steps to reduce the risk of patient cross-contamination, the US FDA recommends in a new draft guidance document.